Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
10 participants
INTERVENTIONAL
2016-04-30
2019-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators will conduct endoscopic injection of umbilical cord mesenchymal stem cells to fistula, observe the recovery of bronchopleural fistula and systemic reactions, to investigate the application of umbilical cord mesenchymal stem cells in the treatment of bronchopleural fistula.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
UCMSC treatment
UCMSC: umbilical cord mesenchymal stem cells
UCMSC
UCMSC: umbilical cord mesenchymal stem cells 3-5\*10\^7/5 ml
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UCMSC
UCMSC: umbilical cord mesenchymal stem cells 3-5\*10\^7/5 ml
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* typical symptom of bronchopleural fistula, such as fever, cough, purulent sputum, weight loss…
* patients present compromised conditions, who can only accept a conservative treatment.
Exclusion Criteria
* with previous treatment of cell therapy, including stem cells.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
INDUSTRY
The Second Affiliated Hospital of Fujian Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yimin Zeng, Dr.
Role: PRINCIPAL_INVESTIGATOR
The Second Affiliated Hospital of Fujian Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Affiliated Hospital of Fujian Medical University
Quanzhou, Fujian, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hongzhi Gao, Dr.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SC-BF
Identifier Type: -
Identifier Source: org_study_id